Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about SPHINGOMYELIN: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Name | SPHINGOMYELIN |
| Key Genes/Proteins | AMYLOID-BETA, APP, CYP46A1, SMPD1 |
| Related Diseases | ALZHEIMER'S DISEASE, CERAMIDE, OXIDATIVE STRESS |
graph TD
SPHINGOMYELIN[SPHINGOMYELIN]
SPHINGOMYELIN -->|treats| APP[APP]
SPHINGOMYELIN -->|activates| CYP46A1[CYP46A1]
SPHINGOMYELIN -->|interacts| AMYLOID_BETA[AMYLOID-BETA]
SPHINGOMYELIN -->|treats| ALZHEIMER_S_DISEASE[ALZHEIMER'S DISEASE]
SPHINGOMYELIN -->|inhibits| OXIDATIVE_STRESS[OXIDATIVE STRESS]
SPHINGOMYELIN -->|inhibits| HIPPOCAMPUS[HIPPOCAMPUS]
SPHINGOMYELIN -->|participates in| CERAMIDE[CERAMIDE]
SMS1[SMS1] -->|catalyzes| SPHINGOMYELIN
SGMS1[SGMS1] -->|catalyzes| SPHINGOMYELIN
Alcohol_Exposure[Alcohol Exposure] -->|downregulates| SPHINGOMYELIN
SMPD1[SMPD1] -->|encodes| SPHINGOMYELIN
CERAMIDE -->|inhibits| SPHINGOMYELIN
SGMS2[SGMS2] -->|involved_in| SPHINGOMYELIN| Target | Relation | Type | Str |
|---|---|---|---|
| APP | treats | gene | 0.65 |
| CYP46A1 | activates | gene | 0.65 |
| CYP46A1 | regulates | gene | 0.65 |
| ALZHEIMER'S DISEASE | treats | disease | 0.65 |
| OXIDATIVE STRESS | inhibits | phenotype | 0.65 |
| HIPPOCAMPUS | inhibits | brain_region | 0.65 |
| HIPPOCAMPUS | regulates | brain_region | 0.65 |
| AMYLOID-BETA | interacts_with | protein | 0.65 |
| HIPPOCAMPUS | expressed_in | brain_region | 0.55 |
| CERAMIDE | participates_in | phenotype | 0.55 |
| HIPPOCAMPUS | associated_with | brain_region | 0.55 |
| FINGOLIMOD | associated_with | drug | 0.45 |
| CEREBELLUM | associated_with | brain_region | 0.45 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Selective Acid Sphingomyelinase Modulation Therapy | 0.920 | neurodegeneration | Lipid raft composition changes in synapt |
| Neutral Sphingomyelinase-2 Inhibition for Synaptic Protectio | 0.844 | neurodegeneration | Lipid raft composition changes in synapt |
| SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysoso | 0.734 | neurodegeneration | What molecular mechanisms link elevated |
| SMPD1 (Acid Sphingomyelinase) Inhibition for Ceramide Reduct | 0.732 | neurodegeneration | How do sphingomyelin/ceramide ratios spe |
| Selective Neutral Sphingomyelinase-2 Inhibition Therapy | 0.731 | neurodegeneration | Lipid raft composition changes in synapt |
| Sphingomyelin Synthase Activators for Raft Remodeling | 0.692 | neurodegeneration | Lipid raft composition changes in synapt |
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Validation: Membrane-Nucleation in iPSC Neurons | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
| Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Pathogenic Variants and Olipudase Alfa Treatment of Patients With Acid Sphingomy [PMID:41692468] | ["Hsu-Heng Lin", "Hui-An Chen", "Shyh-Je | Molecular genetics & genom | 2026 | 0 |
| Multi-omics analysis identifies SMPD1 as a key contributor in sphingolipid pathw [PMID:41428198] | ["Aron Park", "Baeki E Kang", "Eun-Ju Ji | Genes & genomics | 2026 | 0 |
| Coenzyme Q10 Supplementation Modulates Hepatic Lipidomic Alterations and Attenua [PMID:41754105] | Go Y, Joung H, Han SY, Chung J | Nutrients | 2026 | 0 |
| SMPD1 as a Potential Prognostic Biomarker in Glioma Is Associated With an Immuno [PMID:41795144] | Xu Y, Liu X, Xu B, Li Q, Zhang L, Li C, | CNS neuroscience & therapeutic | 2026 | 0 |
| A multi-dimensional bioinformatic dissection of the molecular mechanisms in high [PMID:41191606] | Yu X MD, Lei J MSc, Du X MSc, He Y MSc, | Int J Surg | 2026 | 0 |
| Plasma metabolites may inhibit childhood obesity by regulating ferroptosis throu [PMID:41249848] | Wang JG, Pan XH, Li Y | Int J Obes (Lond) | 2026 | 0 |
| Multi-omics analysis identifies SMPD1 as a key contributor in sphingolipid pathw [PMID:41428198] | Park A, Kang BE, Jin EJ, Kim HJ, Lee CW | Genes Genomics | 2026 | 0 |
| AXL Promotes Ischemic Myelin Repair Through Alleviating Myelin Debris Deposition [PMID:41524160] | Jia J, Gan Y, Li J, Li L, Meng H et al. | Adv Sci (Weinh) | 2026 | 0 |
| Pathogenic Variants and Olipudase Alfa Treatment of Patients With Acid Sphingomy [PMID:41692468] | Lin HH, Chen HA, Lin SJ, Hsu RH, Lee NC | Mol Genet Genomic Med | 2026 | 0 |
| Endogenous Ceramide 24:1 Constrains Th17-Driven Neutrophilic Inflammation by Ant [PMID:41824764] | Liu H, Aili A, Kuang Z, Cao L, Li Z, Sha | Advanced science (Weinheim, Ba | 2026 | 0 |
| Ceramide metabolism in oxidative and glycolytic muscle: Significance for lipid-i [PMID:41707846] | Eurén T, Flockhart M, Strmeň T, Zhou X, | Molecular metabolism | 2026 | 0 |
| Suspected Niemann-Pick disease type B with sea-blue histiocytosis after splenect [PMID:41791926] | Liu W, Qin L, Wang G | Journal of clinical lipidology | 2026 | 0 |
| Olipudase alfa treatment for pediatric acid sphingomyelinase deficiency in Egypt [PMID:41716780] | Arafa NA, Mahfouz A, Anwar S, Marzouk I | Molecular genetics and metabol | 2026 | 0 |
| AXL Promotes Ischemic Myelin Repair Through Alleviating Myelin Debris Deposition [PMID:41524160] | Jia J, Gan Y, Li J, Li L, Meng H, Sun M, | Advanced science (Weinheim, Ba | 2026 | 0 |
| A multi-dimensional bioinformatic dissection of the molecular mechanisms in high [PMID:41191606] | Yu X, Lei J, Du X, He Y, Peng W, Yang R, | International journal of surge | 2026 | 0 |
| Effect of Lactiplantibacillus mudanjiangensis strain isolated from post-fermente [PMID:41270786] | Horie M, Tabata Y, Aiso C, Gotoh Y | Beneficial microbes | 2025 | 0 |
| Bionanoconjugates in Neurodegeneration: Peptide-Nanoparticle Alliances for Next- [PMID:41199078] | ["Ranjitha V", "Kumar A", "Kaalappa P"] | Pharmaceutical research | 2025 | 0 |
| Acid sphingomyelinase activity suggests a new antipsychotic pharmaco-treatment s [PMID:39825014] | Chestnykh D, Mühle C, Schumacher F, Kali | Mol Psychiatry | 2025 | 0 |
| Reduction of sphingomyelinase activity associated with progranulin deficiency an [PMID:40633679] | Boyle NR, Fox SN, Tadepalli AS, Seyfried | Neurobiol Dis | 2025 | 0 |
| Acid sphingomyelinase activity suggests a new antipsychotic pharmaco-treatment s [PMID:39825014] | Chestnykh D, Mühle C, Schumacher F, Kali | Molecular psychiatry | 2025 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning SPHINGOMYELIN in their description or question text